Abstract 187P
Background
The tumour microenvironment (TME) in high-grade serous ovarian cancer (HGSOC) is a complex ecosystem that facilitates ovarian cancer progression. However, further investigation is required to elucidate the precise role of the TME.
Methods
In this study, single-cell RNA sequencing was employed to profile the TME in freshly collected HGSOC samples, comprising two normal ovarian cortex samples and six HGSOC samples.
Results
A total of 55,430 single cells obtained from ovarian and HGSOC tissues were subjected to single-cell RNA sequencing (scRNA-seq). The cells were divided into seven clusters, comprising B cells, T and NK cells, myeloid cells, endothelial cells, fibroblasts, epithelial cells and mast cells. The proportion of B cells, myeloid cells, mast cells and T & NK cells was greater in HGSOC samples than in ovary cortex samples, whereas the percentage of epithelial cells was lower in the former. The analysis of intercommunication of epithelial cells with other cell clusters indicated that the interactions between epithelial cells and fibroblast cells, T & NK cells, B cells as well as myeloid cells were enhanced in in HGSOC samples comparing ovary cortex samples. Additionally, we identified a subcluster of epithelial cells (E7) and a subcluster of fibroblast cells (F7) that were implicated in tumour formation. Finally, we examined the intercommunication between E7 and F7. One of the most significant ligand-receptor signals identified was THBS2-CD74.
Conclusions
The results clearly demonstrated an increase in immune cell percentage in ovarian cancer tissue. Malignant cell clusters, designated as fibroblast cells F7 and epithelial cells E7, were also identified. Among the interactions between F7 and E7, the THBS2-CD74 signal emerged as a crucial factor in the tumourigenesis of HGSOC.
Legal entity responsible for the study
Beijing Obstetrics and Gynecology, Capital Medical University.
Funding
National Natural Science Foundation of China (No. 82373397), the Capital’s Funds for Health Improvement and Research (No. 2022-2-2116), Beijing Municipal Administration of Hospitals Incubating Program (No.PX2022057) and Beijing Obstetrics and Gynecology Hospital, Capital Medical University (No. FCYY201915).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract